Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional coh
- PDF / 1,877,038 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 156 Views
ORIGINAL INVESTIGATION
Cardiovascular Diabetology Open Access
Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi‑institutional cohort study and meta‑analysis Kai‑Cheng Chang1,2, Shih‑Chieh Shao2,3, Shihchen Kuo4, Chen‑Yi Yang2, Hui‑Yu Chen1, Yuk‑Ying Chan5 and Huang‑Tz Ou2,6,7*
Abstract Background: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is lim‑ ited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. Methods: We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016–2018 in Taiwan and followed up until 2019. Effectiveness outcomes were assessed at every 3 months in the 1-year follow-up. Propen‑ sity score techniques were applied to enhance between-group comparability. Significant differences in changes of effectiveness outcomes between treatment groups during the follow-up were examined and further analyzed using mixed-model repeated-measures approaches. Results: A total of 1512 subjects receiving dulaglutide and 1513 subjects receiving liraglutide were identified. At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: − 1.06%, p
Data Loading...
